Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dan Chen, Jianxuan Zou, Yunhui Zong, Huimin Meng, Gangli An & Lin Yang. (2016) Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacology and Immunotoxicology 38:3, pages 175-183.
Read now
Read now
Maria Bai, Vassilios Panoulas, Alexandra Papoudou-Bai, Nikolaos Horianopoulos, Panagiotis Kitsoulis, Kalliopi Stefanaki, Dimitra Rontogianni, Niki John Agnantis & Panagiotis Kanavaros. (2006) B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leukemia & Lymphoma 47:3, pages 495-501.
Read now
Read now
László Kopper. (2000) Syndecans and the Lymphoid System. Leukemia & Lymphoma 38:3-4, pages 271-281.
Read now
Read now
Articles from other publishers (41)
L. Baert, B. Manfroi, M. Quintero, O. Chavarria, P.V. Barbon, E. Clement, A. Zeller, T. Van Kuppevelt, N. Sturm, J. Moreaux, A. Tveita, B. Bogen, T. McKee & B. Huard. (2023) 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness. Matrix Biology 120, pages 60-75.
Crossref
Crossref
Fang Lu, Kayla A. Martin, Samantha S. Soldan, Andrew V. Kossenkov, Priyankara Wickramasinghe, Olga Vladimirova, Alessandra De Leo, Cindy Lin, Yulia Nefedova & Paul M. Lieberman. (2021) Defective Epstein-Barr Virus Genomes and Atypical Viral Gene Expression in B-Cell Lines Derived from Multiple Myeloma Patients. Journal of Virology 95:13.
Crossref
Crossref
Lisa Smart & Dez Hughes. (2021) The Effects of Resuscitative Fluid Therapy on the Endothelial Surface Layer. Frontiers in Veterinary Science 8.
Crossref
Crossref
Nourhan Hassan, Burkhard Greve, Nancy A. Espinoza-Sánchez & Martin Götte. (2021) Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer. Cellular Signalling 77, pages 109822.
Crossref
Crossref
Tingting Zhao, Li Cui, Xiangqian Yu, Zhonghai Zhang, Qi Chen & Xiuguo Hua. (2020) Proteome Analysis Reveals Syndecan 1 Regulates Porcine Sapelovirus Replication. International Journal of Molecular Sciences 21:12, pages 4386.
Crossref
Crossref
Nancy A. Espinoza-Sánchez & Martin Götte. (2020) Role of cell surface proteoglycans in cancer immunotherapy. Seminars in Cancer Biology 62, pages 48-67.
Crossref
Crossref
Monica SharmaSeema TyagiPreeti TripathiTulika Seth. (2018) Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations. Blood Research 53:3, pages 205.
Crossref
Crossref
Xiangrong Cui, Xuan Jing, Qin Yi, Chunlan Long, Jie Tian & Jing Zhu. (2017) Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer. Oncotarget 8:67, pages 111444-111455.
Crossref
Crossref
C Urbinati, E Grillo, P Chiodelli, C Tobia, F Caccuri, S Fiorentini, G David & M Rusnati. (2016) Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway. Oncogene 36:18, pages 2609-2618.
Crossref
Crossref
Anil Kumar Jaiswal, Mohanraj Sadasivam & Abdel Rahim A Hamad. (2017) Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis. World Journal of Diabetes 8:4, pages 130.
Crossref
Crossref
Arthur ZimmermannArthur Zimmermann. 2017. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract
1541
1576
.
Arthur ZimmermannArthur Zimmermann. 2016. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract
1
36
.
Vardit Kram & Marian F. Young. 2014. Osteogenesis Imperfecta. Osteogenesis Imperfecta
85
95
.
Christoph Stein, Ingo Schubert & Georg H. Fey. (2012) Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. Antibodies 1:1, pages 88-123.
Crossref
Crossref
?lknur Ak & Zafer Gulbas. (2010) F-18 FDG uptake of bone marrow on PET/CT scan: it?s correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Annals of Hematology 90:1, pages 81-87.
Crossref
Crossref
Homare Eda, Katsuhiko Aoki, Soki Kato, Yutaka Okawa, Koji Takada, Takaaki Tanaka, Keishi Marumo & Kiyoshi Ohkawa. (2010) The proteasome inhibitor bortezomib inhibits FGF‐2‐induced reduction of TAZ levels in osteoblast‐like cells. European Journal of Haematology 85:1, pages 68-75.
Crossref
Crossref
Sachin C. Sarode, Gargi S. Sarode & Anuprita Patil. (2010) Plasmablastic lymphoma of the oral cavity: A review. Oral Oncology 46:3, pages 146-153.
Crossref
Crossref
Vlastimil Scudla, Tomas Pika, Marie Budikova, Pavla Petrova, Jaroslav Bacovsky, Karel Srovnalik, Jiri Minarik & Katerina Langova. (2009) THE RELATIONSHIP BETWEEN SOME SOLUBLE OSTEOGENIC MARKERS, ANGIOGENIC CYTOKINES/OTHER BIOLOGICAL PARAMETERS AND THE STAGES OF MULTIPLE MYELOMA EVALUATED ACCORDING TO THE DURIE-SALMON AND INTERNATIONAL PROGNOSTIC INDEX STRATIFICATION SYSTEMS. Biomedical Papers 153:4, pages 275-282.
Crossref
Crossref
Tomas Pika, Jiri Minarik, Petr Schneiderka, Marie Budikova, Katerina Langova, Pavel Lochman, Jaroslav Bacovsky, Vera Farbiakova & Vlastimil Scudla. (2008) THE CORRELATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL MARKERS IN MULTIPLE MYELOMA. Biomedical Papers 152:1, pages 61-64.
Crossref
Crossref
Samer Z. Al-Quran, Lijun Yang, James M. Magill, Raul C. Braylan & Vonda K. Douglas-Nikitin. (2007) Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Human Pathology 38:12, pages 1779-1787.
Crossref
Crossref
Gui Su, Stacy A. Blaine, Dianhua Qiao & Andreas Friedl. (2007) Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 Activation. Journal of Biological Chemistry 282:20, pages 14906-14915.
Crossref
Crossref
Peter Liebisch & Hartmut Döhner. (2006) Cytogenetics and molecular cytogenetics in multiple myeloma. European Journal of Cancer 42:11, pages 1520-1529.
Crossref
Crossref
Elke Pogge von StrandmannHinrich P. HansenKatrin S. ReinersRoland SchnellPeter BorchmannSabine MerkertVenkateswara R. SimhadriAndreas DraubeMarcel ReiserIngvill PurrMichael HallekAndreas Engert. (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107:5, pages 1955-1962.
Crossref
Crossref
Jean-Philippe Dales, Anass Harket, Denis Bagn?res, Lucile Andrac-Meyer, Luc Xerri, Yves Frances & Colette Taranger-Charpin. (2005) Lymphome plasmoblastique du sujet infect? par le VIH : ? propos d?un cas tr?s inhabituel de localisation cutan?e. Annales de Pathologie 25:1, pages 45-49.
Crossref
Crossref
Sharon SagnellaEric AndersonNaomi SanabriaRoger E. MarchantKandice Kottke-Marchant. (2005) Human Endothelial Cell Interaction with Biomimetic Surfactant Polymers Containing Peptide Ligands from the Heparin Binding Domain of Fibronectin. Tissue Engineering 11:1-2, pages 226-236.
Crossref
Crossref
Robert A. Vescio & James R. Berenson. 2004. Biology and Management of Multiple Myeloma. Biology and Management of Multiple Myeloma
37
53
.
John R. Couchman. (2003) Syndecans: proteoglycan regulators of cell-surface microdomains?. Nature Reviews Molecular Cell Biology 4:12, pages 926-938.
Crossref
Crossref
Kewal AsosinghHendrik De RaeveIvan Van RietBenjamin Van CampKarin Vanderkerken. (2003) Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 101:8, pages 3136-3141.
Crossref
Crossref
İ. AK, V. Aslan, E. Vardareli & Z. Gülbaş. (2003) Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells. Annals of Hematology 82:2, pages 88-92.
Crossref
Crossref
C.M. Flaitz, C.M. Nichols, D.M. Walling & M.J. Hicks. (2002) Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncology 38:1, pages 96-102.
Crossref
Crossref
Kai Neben, Thomas Moehler, Alwin Kraemer, Axel Benner, Gerlinde Egerer, Anthony D. Ho & Hartmut Goldschmidt. (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology 115:3, pages 605-608.
Crossref
Crossref
D Gupta, SP Treon, Y Shima, T Hideshima, K Podar, YT Tai, B Lin, S Lentzsch, FE Davies, D Chauhan, RL Schlossman, P Richardson, P Ralph, L Wu, F Payvandi, G Muller, DI Stirling & KC Anderson. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:12, pages 1950-1961.
Crossref
Crossref
Mikihiro Fujiya, Jiro Watari, Toshifumi Ashida, Mitsunori Honda, Hiroki Tanabe, Takanori Fujiki, Yusuke Saitoh & Yutaka Kohgo. (2005) Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal Cancer. Japanese Journal of Cancer Research 92:10, pages 1074-1081.
Crossref
Crossref
Dirk H�nemann, Manik Chatterjee, Rocco Savino, Kurt Bommert, Renate Burger, Martin Gramatzki, Bernd D�rken & Ralf C. Bargou. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. International Journal of Cancer 93:5, pages 674-680.
Crossref
Crossref
J.F. Manakil, P.B. Sugerman, H. Li, G.J. Seymour & P.M. Bartold. (2016) Cell-surface Proteoglycan Expression by Lymphocytes from Peripheral Blood and Gingiva in Health and Periodontal Disease. Journal of Dental Research 80:8, pages 1704-1710.
Crossref
Crossref
Anu Anttonen, Päivi Heikkilä, Mikael Kajanti, Markku Jalkanen & Heikki Joensuu. (2001) High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32:3, pages 297-305.
Crossref
Crossref
Ralph D. Sanderson. (2001) Heparan sulfate proteoglycans in invasion and metastasis. Seminars in Cell & Developmental Biology 12:2, pages 89-98.
Crossref
Crossref
Carina SeidelMagne BørsetØyvind HjertnerDianjun CaoNiels AbildgaardHenrik Hjorth-HansenRalph D. SandersonAnders WaageAnders Sundan. (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96:9, pages 3139-3146.
Crossref
Crossref
Magne BørsetØyvind HjertnerShmuel YaccobyJoshua EpsteinRalph D. Sanderson. (2000) Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96:7, pages 2528-2536.
Crossref
Crossref
Sunil C Kaul, Takashi Sugihara, Akiko Yoshida, Hitoshi Nomura & Renu Wadhwa. (2000) Gros1, a potential growth suppressor on chromosome 1: its identity to basement membrane-associated proteoglycan, leprecan. Oncogene 19:32, pages 3576-3583.
Crossref
Crossref
Marilyn L. Fitzgerald, Zihua Wang, Pyong Woo Park, Gillian Murphy & Merton Bernfield. (2000) Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase. The Journal of Cell Biology 148:4, pages 811-824.
Crossref
Crossref